Treatment with anti-inflammatories drugs in Covid19 high-risk patient, disease evolution, clinical case

Abstract

On March 11, 2020, covid 19 was considered a pandemic by the WHO, that same day the first case in Cuba is confirmed from an Italian tourist. In the province of Las Tunas during the month of August there is a deliberate increase in the number of cases straining the health system, we refer to the medical treatment of a 32-year-old male patient with a history of insulin-dependent diabetes mellitus, extreme obesity, arterial hypertension and adverse reaction to thiomersal which prevented him from using anti-covid vaccines, which developed the severe form of the disease (acute respiratory distress syndrome moderated by viral bronchopneumonia associated with covid) , diabetic ketoacidosis) he had clinical and laboratory signs of poor prognosis, after therapy with innovative drugs specifically anti-inflammatory (jusvinza) developed in Cuba for the treatment of other conditions but with good results in severely ill patients with covid 19, presented favorable evolution and medical discharge with mild sequelae of the disease.